Transaction aims to provide broader access to high-quality testing and laboratory services to communities across the ...

BioNexus Gene Lab Corp. (“BGLC” or the “Company”), an emerging provider of precision oncology diagnostics with expanding operations across Southeast Asia, today announced it has entered into a ...

Franklin, Tenn.-based Community Health Systems has completed the sale of select ambulatory outreach laboratory assets to Labcorp for $194 million in cash. The deal includes certain assets of ...

Labcorp Holdings Inc. LH, or Labcorp, continues to expand its business in specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology. The company’s strategic ...

Community Health ( ($CYH) ) has provided an update. On December 1, 2025, Community Health Systems, Inc. completed the sale of select assets and ...

Investing.com -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) stock surged 10% after the precision oncology diagnostics provider secured a $500 million equity facility from ARC Group International.

The 36-month facility allows BioNexus to issue and sell registered shares of its common stock to ARC at its sole discretion. As compensation for ARC’s commitment, BioNexus issued 175,000 shares of ...

BioNexus Gene Lab Corp. (NASDAQ:BGLC) climbed 10% in premarket trading on Tuesday after the precision oncology diagnostics firm announced it had obtained a $500 million equity facility from ARC Group ...

Summary • BioNexus Gene Lab Corp (BGLC) shares rose 30% to $5.76 in pre-market trading after a strategic alliance ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...

The global clinical trials market is anticipated to grow at a CAGR of 6-7% from 2024 to 2029. This growth is driven by the ...